AXT Inc
AXTI
$56.51
+15.73%
AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers, serving the semiconductor industry. The company differentiates itself by providing alternative or specialty materials such as indium phosphide and gallium arsenide substrates, catering to high-performance applications. Currently, the stock is attracting attention due to its massive 1,734% price surge over the past year, driven by AI-related demand for its substrates, though recent volatility and a stock offering have introduced dilution concerns and profit-taking risks.…
AXTI
AXT Inc
$56.51
Related headlines
Investment Opinion: Should I buy AXTI Today?
Rating: Hold. The thesis is that AXT's AI-driven growth story is compelling, but the stock's extreme volatility, dilution, and lack of profitability make it too risky for a Buy at current levels. The analyst consensus is Buy with an average target of $96.50, implying 110% upside, but recent downgrades from Needham and B. Riley introduce caution.
Supporting Evidence: Revenue grew 39% YoY, but the sequential decline and negative FCF of -$27.98M are concerning. The trailing PS of 8.13 is above the industry average, but the forward PS of 1.88 (based on $382M revenue estimates) suggests deep value if estimates are met. Gross margin improved to 29.6% from -6.4%, showing operational progress. However, the stock's 50% monthly decline and beta of 1.87 indicate high risk.
Risks & Conditions: The biggest risks are failure to achieve revenue estimates and further dilution. This Hold would upgrade to Buy if the stock stabilizes above $50 and Q2 2026 revenue exceeds $30M, or downgrade to Sell if revenue guidance disappoints. Valuation verdict: The stock is overvalued on trailing metrics but potentially undervalued on forward estimates if growth materializes. Given the uncertainty, a Hold is appropriate.
Sign up to view all
AXTI 12-Month Price Forecast
AXT is at a crossroads. The AI-driven growth narrative is intact, but the stock's recent 50% plunge and dilution have damaged sentiment. The forward PS of 1.88 implies massive growth expectations that may be unrealistic. The neutral stance reflects the balance between the potential for a turnaround if revenue materializes and the risk of further decline if it doesn't. Key catalysts to watch are Q2 2026 earnings and any updates on customer contracts. An upgrade to bullish would require evidence of accelerating revenue and margin expansion; a downgrade to bearish would follow missed estimates or additional dilution.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AXT Inc's 12-month outlook, with a consensus price target around $96.50 and implied upside of +70.8% versus the current price.
Average Target
$96.50
0 analysts
Implied Upside
+70.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$73 - $125
Analyst target range
AXT is covered by 4 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.8 (1=Strong Buy, 5=Sell). The average target price is $96.50, implying a substantial 110.4% upside from the current price of $45.86. The distribution shows 1 strong buy, 2 buys, and 1 hold (based on ratings data: Wedbush Outperform, Needham Hold, B. Riley Neutral). The consensus leans bullish, but the recent downgrades from Needham (Buy to Hold) and B. Riley (Buy to Neutral) introduce caution. The target price range spans from a low of $73.00 to a high of $125.00. The high target of $125 assumes a recovery to near the 52-week high, likely driven by AI substrate demand and margin expansion. The low target of $73 still implies 59% upside, suggesting analysts see value even in a conservative scenario. The wide spread ($52) indicates high uncertainty, reflecting the stock's extreme volatility and the binary nature of its growth story. Recent institutional actions show a mix of upgrades and downgrades, with Wedbush maintaining Outperform, while Needham and B. Riley have turned more cautious, signaling diverging views on the risk/reward.
Bulls vs Bears: AXTI Investment Factors
AXT presents a high-risk, high-reward opportunity. The bull case rests on explosive AI-driven revenue growth, improving margins, and strong analyst support with 110% upside to the average target. However, the bear case is equally compelling: massive dilution, negative cash flow, extreme volatility, and a 50% monthly decline suggest the stock is in a correction. The single most important tension is whether the company can deliver on the revenue estimates of $382M for 2026—a 10x increase from current levels. If it does, the forward PS of 1.88 would be a deep value; if it fails, the stock could fall to its 52-week low of $1.85. Currently, the evidence is balanced but tilted slightly bearish due to the recent price action and dilution, though the long-term AI thesis remains intact.
Bullish
- Massive Revenue Growth Trajectory: Revenue surged 39.1% YoY to $26.9M in Q1 2026, driven by AI-related demand for compound semiconductor substrates. Analysts project revenue of $382M for fiscal 2026, implying a 10x increase from current run-rate, reflecting expectations of exponential growth.
- Analyst Consensus Bullish with 110% Upside: The average analyst target of $96.50 implies 110.4% upside from the current price of $45.86. With 3 out of 4 analysts rating it Buy or Strong Buy, the Street sees significant value despite recent volatility.
- Gross Margin Improvement Signals Operating Leverage: Gross margin improved from -6.4% in Q1 2025 to 29.6% in Q1 2026, indicating better cost management and product mix. As revenue scales, fixed costs are being absorbed more efficiently, paving the way toward profitability.
- AI-Driven Demand for Specialty Substrates: AXT's indium phosphide and gallium arsenide substrates are critical for high-speed communications and AI chips. The 1,734% one-year price surge reflects market belief that AXT is a key enabler of next-gen semiconductor technologies.
Bearish
- Massive Stock Dilution from Equity Offering: AXT issued $95M in common stock in Q4 2025, increasing shares outstanding by over 20% (from 43.8M to 53.3M). This dilution has pressured the stock price and will weigh on EPS even as revenue grows.
- Still Unprofitable with Negative Free Cash Flow: Net loss of -$1.62M in Q1 2026, though narrowing, and TTM free cash flow of -$27.98M indicate the company is still burning cash. Without sustained profitability, the stock remains speculative.
- Extreme Volatility and Momentum Reversal: The stock has fallen 50.2% in the past month and 44.5% in three months, with a beta of 1.87. This severe pullback from the 52-week high of $143.16 suggests profit-taking and potential trend reversal.
- Valuation Premium on Trailing Sales: Trailing PS ratio of 8.13 is well above the semiconductor industry average of 3-5x, implying high growth expectations. If revenue growth disappoints, the stock could see further multiple compression.
AXTI Technical Analysis
AXTI has experienced a dramatic uptrend over the past year, with a 1-year price change of +1,734.4%, far outpacing the S&P 500's +18.35%. The current price of $45.86 sits at 31.1% of its 52-week range ($1.85 low to $143.16 high), indicating a significant pullback from the highs. This positioning near the lower end of the range suggests the stock is in a correction phase, potentially offering a value entry if the long-term trend resumes, but also reflecting a loss of momentum. Short-term momentum is sharply negative, with a 1-month price change of -50.2% and a 3-month change of -44.5%, contrasting sharply with the 1-year gain. This divergence signals a severe pullback or trend reversal, as the stock has given back a substantial portion of its gains. The relative strength versus the S&P 500 is also deeply negative over 1-month (-50.5%) and 3-month (-49.1%), confirming broad-based selling pressure. The 52-week low of $1.85 provides a distant support level, while the 52-week high of $143.16 is a major resistance. A break above $143.16 would signal a resumption of the uptrend, while a breakdown below recent lows near $45 could accelerate losses. The stock's beta of 1.867 indicates it is 86.7% more volatile than the market, amplifying both upside and downside moves, which is critical for risk management.
Beta
1.87
1.87x market volatility
Max Drawdown
-67.6%
Largest decline past year
52-Week Range
$2-$143
Price range past year
Annual Return
+2335.8%
Cumulative gain past year
| Period | AXTI Return | S&P 500 |
|---|---|---|
| 1m | -33.2% | +0.2% |
| 3m | -35.0% | +5.2% |
| 6m | +215.3% | +8.6% |
| 1y | +2335.8% | +19.0% |
| ytd | +237.2% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXTI Fundamental Analysis
Revenue has shown a mixed trajectory, with the most recent quarter (Q1 2026) reporting $26.924 million, up 39.1% year-over-year from $19.356 million in Q1 2025. However, revenue declined sequentially from $27.955 million in Q3 2025, indicating some deceleration. The company's revenue is driven by two segments: Substrates ($19.281 million) and Raw Materials and Other ($7.643 million), with substrates being the primary growth driver. The positive YoY growth suggests improving demand, but the sequential decline raises questions about sustainability. The company remains unprofitable, with a net loss of -$1.62 million in Q1 2026, though this loss narrowed significantly from -$8.798 million in Q1 2025. Gross margin improved to 29.63% in Q1 2026 from -6.41% a year ago, indicating better cost management and product mix. However, operating margin remains negative at -5.89%, and net margin is -6.02%, reflecting ongoing operational inefficiencies. The trajectory toward profitability is positive but still distant. AXT has a debt-to-equity ratio of 0.237, indicating moderate leverage, and a current ratio of 2.72, suggesting adequate liquidity. However, free cash flow is negative at -$27.978 million over the trailing twelve months, and operating cash flow was -$11.684 million in Q1 2026. The company relies on external financing, as evidenced by $95.059 million in common stock issued in Q4 2025, which dilutes shareholders. ROE is -7.78%, reflecting poor returns on equity.
Quarterly Revenue
$26924000.0B
2026-03
Revenue YoY Growth
+39.1%
YoY Comparison
Gross Margin
29.6%
Latest Quarter
Free Cash Flow
$-27978000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXTI Overvalued?
Since net income is negative (TTM net loss), the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 8.13, while forward PS (based on estimated revenue of $382.1 million) is approximately 1.88, implying a significant compression if revenue estimates are met. The gap between trailing and forward PS suggests the market expects substantial revenue growth to justify the current valuation. Compared to the semiconductor industry average PS ratio (typically around 3-5x), AXT's trailing PS of 8.13 represents a premium of 63-171%, reflecting high growth expectations. However, the forward PS of 1.88 would be a discount, indicating that the market is pricing in a dramatic revenue ramp. The premium may be justified by the company's 39% YoY revenue growth and AI-driven demand, but the negative profitability raises caution. Historically, AXT's PS ratio has ranged from near 3x in early 2025 to over 112x in Q1 2026. The current trailing PS of 8.13 is well below the historical peak of 112.84, suggesting the stock has de-rated significantly from its euphoric highs. This could indicate a value opportunity if the company delivers on growth, or it may reflect deteriorating fundamentals if the revenue trajectory disappoints.
PE
-33.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-59.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AXT remains unprofitable with a net loss of -$1.62M in Q1 2026 and negative free cash flow of -$27.98M TTM. The company's reliance on external financing is evident from the $95M stock offering in Q4 2025, which diluted shareholders by over 20%. While gross margin improved to 29.6%, operating margin is still -5.9%, indicating that operational inefficiencies persist. The sequential revenue decline from $27.96M in Q3 2025 to $26.92M in Q1 2026 raises concerns about demand sustainability. With a debt-to-equity ratio of 0.24, leverage is manageable, but the negative ROE of -7.78% reflects poor returns on equity.
Market & Competitive Risks: The stock's beta of 1.867 makes it highly sensitive to market swings, and the 50.2% monthly decline shows extreme momentum risk. The trailing PS of 8.13 is a premium to the semiconductor industry average of 3-5x, leaving room for multiple compression if growth slows. Recent news of a stock offering and insider selling (Pacific Ridge's 1.7M share sale) signals that early investors are taking profits. Additionally, the company faces competition from larger substrate manufacturers and potential technology shifts that could reduce demand for its specialty materials.
Worst-Case Scenario: If revenue growth stalls (e.g., due to AI demand cooling or competition), the stock could retest its 52-week low of $1.85, representing a -96% decline from the current price of $45.86. This scenario would likely involve the company missing revenue estimates, burning through cash, and needing further dilutive financing. The analyst low target of $73 implies a more moderate -59% downside, but the 52-week low is the ultimate floor. Given the stock's history of extreme volatility (max drawdown of -67.64%), a -96% loss is possible if the AI thesis unravels.
FAQ
The key risks are: 1) Financial risk: the company is unprofitable with negative free cash flow of -$27.98M TTM, and may need further dilutive financing. 2) Valuation risk: the trailing PS of 8.13 is a premium to peers, leaving room for multiple compression if growth disappoints. 3) Market risk: with a beta of 1.87, the stock is highly volatile and has already fallen 50% in one month. 4) Company-specific risk: the stock offering and insider selling signal that early investors are taking profits, which could pressure the stock further. The most severe risk is a -96% decline to the 52-week low of $1.85 if the AI thesis fails.
The 12-month outlook is uncertain. The bull case (25% probability) sees the stock reaching $96.50-$143.16, driven by strong AI demand and margin expansion. The base case (50% probability) targets $73-$96.50, assuming moderate growth and stable margins. The bear case (25% probability) sees the stock falling to $1.85-$73 if growth disappoints. The most likely scenario is the base case, where the stock trades near the analyst average target of $96.50, but the wide range reflects high uncertainty. Key assumptions include revenue growth of at least 50% YoY and gross margins holding above 30%.
AXTI's trailing PS ratio of 8.13 is above the semiconductor industry average of 3-5x, suggesting it is overvalued based on historical sales. However, the forward PS ratio of 1.88 (based on estimated revenue of $382M) implies deep value if those estimates are achieved. The market is pricing in a dramatic revenue ramp, which is a high bar. Compared to its own history, the current PS is well below the peak of 112x seen in early 2026, indicating the stock has de-rated significantly. Overall, AXTI appears overvalued on trailing metrics but potentially undervalued on forward estimates, making the valuation highly dependent on future growth.
AXTI is a high-risk, high-reward stock. The analyst consensus is Buy with an average target of $96.50, implying 110% upside from $45.86. However, the stock has fallen 50% in the past month and the company is still unprofitable with negative free cash flow. The biggest downside risk is that revenue growth fails to meet aggressive estimates, leading to further multiple compression. For aggressive investors with a long-term horizon and high risk tolerance, AXTI could be a good buy if they believe in the AI substrate story. For conservative investors, it is too speculative. The risk/reward is attractive only if the company delivers on its growth promises.
AXTI is more suitable for long-term investment due to its extreme volatility and speculative nature. The stock's beta of 1.87 and 50% monthly decline make it too risky for short-term trading unless one has a high risk tolerance and active risk management. The company is in an early growth stage with negative earnings, so it may take several years to reach profitability. A minimum holding period of 3-5 years is recommended to allow the AI-driven growth story to play out. Short-term traders may find opportunities in the volatility, but the risk of sharp reversals is high.